In March 2022, CDC changed its data collection schedule to every 8 weeks for the nationwide COVID-19 infection-induced antibody
seroprevalence (commercial laboratory) survey. It now includes information on antibodies for pediatric age groups (ages 6 months
to 17 years). Adult antibody updates will be based on the
national blood donor seroprevalence study.
This dashboard, which includes information for all age groups, has been updated through February 2022. Updated pediatric
seroprevalence information from March 2022 is available here. CDC currently plans to end
the nationwide SARS-CoV-2 antibody studies in December 2022.